Mayne Pharma Group Limited
MAYNF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$216.11M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $216.11 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $0.3 |
| Beta | 1 |
| Outstanding Shares | 81,245,827 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 8.58 |
|---|---|
| PEG | -5.44 |
| Price to Sales | 0.21 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$-0.24
Consensus analyst estimateRevenue Estimate
$115.39 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
$-0.09
Consensus analyst estimateRevenue Estimate
$144.62 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Mayne Pharma Group Limited
450 employees
CEO: Aaron Gray
Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Aus...